Benefit of Adding Cureety TechCare Telemonitoring to Usual Care During Injectable Anticancer Treatment
- Conditions
- Adult Patients Initiating Injectable Anticancer
- Registration Number
- NCT06371911
- Lead Sponsor
- Centre Francois Baclesse
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion criteria<br><br> - Patients that have provided written informed consent for study participation before<br> any trial-related activities.<br><br> - Patients aged 18 years or older.<br><br> - Patients initiating injectable anticancer treatment (chemotherapy, immunotherapy,<br> targeted therapies etc.).<br><br> - Patients with the capacity, personally (e.g., language and capacity to use the<br> application), and in terms of infrastructure (internet access, possessing a smart<br> phone etc.) to perform Cureety telemonitoring.<br><br> - Patient affiliated to an appropriate social security system<br><br>Non-inclusion criteria<br><br> - Exclusive oral cancer treatment<br><br> - Patient with dysphonia or difficulty communicating orally<br><br> - Patient benefiting from injectable cancer treatment as part of a clinical trial<br><br> - Inability to undergo trial monitoring for geographical, social or psychological<br> reasons<br><br> - Any associated medical or psychological condition that could compromise the<br> patient's ability to participate in the study<br><br> - Patient deprived of freedom or under guardianship
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of adding Cureety telemonitoring to usual care
- Secondary Outcome Measures
Name Time Method